Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma.
Forty-nine patients were treated with either 3 x 75 MBq 89Sr or saline as placebo. Analysis of results 1 to 3 years after therapy revealed the ineffectiveness of 89Sr to relieve pain from metastases. Unexpectedly, a higher survival rate was found after Sr application (46% vs 4% after 2 years). Covariate analysis underlines the effect of 89Sr therapy on life expectation.
Buchali
K
K
Klinik für Nuklearmedizin, Bereich Medizin (Charitè), Humboldt-Universität, Berlin, German Democratic Republic.
Correns
H J
HJ
Schuerer
M
M
Schnorr
D
D
Lips
H
H
Sydow
K
K
D000368:Aged; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011897:Random Allocation; D013326:Strontium Radioisotopes / Q000627:therapeutic use*
D013326:Strontium Radioisotopes